Clinical Trial Search

Primary: Number of Treatment Emergent Severe or BG (Blood Glucose) Confirmed Symptomatic Hypoglycaemic Episodes During the Maintenance Period — 2772; 3126 Event — p=<0.0001

Primary: Plasma Lamivudine Area Under the Plasma Concentration Time Curve (AUC) From Time Zero to the Last Quantifiable Time Point (AUC[0-t]), AUC From Time Zero Extrapolated to…

Primary: Event Free Survival Probability — 0.88; 0.87; 0.88 Probability

Primary: Percentage of Subjects Achieving Specific Thresholds of Antibody Concentrations for Subjects in Enrollment Group 1 — 38; 30; 30; 29 percentage of subjects

Primary: Change in Withdrawal Symptoms With Placebo and With Ondansetron — -22.08; -42.71 Percent change

Primary: Overall Response Rate — 1 Participants

Primary: Present Pain Intensity — 6.5; 6.3; 3.1; 3.7 Units on a scale

Primary: Change in Breath Alcohol Content Between the Estimated Level and the Actual Level as Measured by an Alco Sensor IV Device — 0.01; -0.01 percent blood alcohol content…

Primary: Cumulative Opioid Consumption — 97; 117 mg morphine equivalents — p=0.08

Primary: Slope of the Second Phase Decline in Plasma HCV Ribonucleic Acid (RNA) Levels During Treatment — 0.0036; 0.0046; 0.0051 1/day — p=0.311

Primary: Change in Fat mtDNA Content — -169; 321 copies/cell

Primary: The Mean Difference in CVI Between Pre-laryngoscopy and Post-laryngoscopy for Each of the Four Rocuronium Groups — 2.40; 1.39; 0.48; 0.17 units on a scale — p=< 0.05

Primary: Change in CSF Ceramide Between Baseline and Week 24 (C18:0 Levels) - Intent to Treat — -30.78; 4.16; -12.17; -30.56 ng/mL — p=0.893

Primary: Safety and Tolerability of HSC835 for Clinical Use Were Measured by Infusional Toxicity (Within First 48 Hours After Transplant) and Absence of Graft Failure After 32…

Primary: Number of Participants From Each Arm Who Received Influenza Vaccine Vaccine — 6; 6; 8; 6 Participants